Welcome to our dedicated page for The Oncology Institute news (Ticker: TOIIW), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute Inc (NASDAQ: TOIIW) delivers community-focused cancer care through innovative value-based models and clinical research integration. This news hub provides investors and healthcare professionals with essential updates on operational developments, strategic partnerships, and patient care advancements.
Access authoritative reporting on TOI's financial performance, clinical trial milestones, and service expansions. Our curated collection includes press releases covering earnings announcements, new clinic openings, research collaborations, and healthcare policy impacts relevant to oncology care delivery.
Key updates feature developments in infusion center operations, progress in value-based payment models, and community health initiatives. Stay informed about TOI's role in outpatient cancer treatment innovation and its growing network of care centers across strategic regions.
Bookmark this page for real-time access to verified TOIIW disclosures and analysis-free reporting. Check regularly for essential updates that matter to stakeholders in oncology care and value-driven healthcare investments.
The Oncology Institute (NASDAQ: TOI) reported its Q2 2024 financial results and updated full-year guidance. Key highlights include:
- 22.9% increase in consolidated revenue to $99 million
- 76% growth in Dispensary segment revenue
- Net loss of $15.5 million, improved from $16.9 million in Q2 2023
- Adjusted EBITDA of $(8.7) million
- Cash and equivalents of $46.4 million as of June 30, 2024
TOI signed 3 new capitation contracts across 2 states, bringing the total to 10 new contracts in 2024. The company is exploring strategic alternatives to maximize shareholder value. Despite a decrease in gross profit, TOI expects significant improvement in net loss and adjusted EBITDA in H2 2024, driven by improving IV margins and newly signed capitated contracts going live in Q3.
The Oncology Institute (TOI), a leading value-based oncology group in the United States, has announced its second quarter 2024 earnings release date and conference call details. The company will release its financial results on Tuesday, August 13, 2024, after the market close. This will be followed by a conference call at 5:00 p.m. Eastern Time on the same day.
Investors can access the call by dialing 1-877-407-0789 (US) or 1-201-689-8562 (international). A replay will be available until August 20, 2024, accessible via 1-844-512-2921 (US) or 1-412-317-6671 (international) with passcode 13747491. Additionally, a simultaneous webcast will be available on the company's Investor Relations website.
The Oncology Institute (NASDAQ: TOI) will participate in two major investor conferences. CEO Dr. Daniel Virnich will represent TOI at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00am ET in New York City. He will also join the Truist Securities Healthcare Disruptors & Digital Health Summit on June 26, 2024, at 1:00pm ET, also in New York City. Interested parties can access live webcasts and replays through the company's Investor Relations website.
The Oncology Institute (NASDAQ: TOI) has announced that its executives will participate in multiple panel presentations at the APG 2024 Spring Conference in San Diego. Dr. Yale Podnos, Chief Medical Officer, will discuss the use of artificial intelligence in oncology practices during the breakout session titled 'AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients'. Additionally, CEO Dr. Daniel Virnich will join a panel discussing global risk management in pharmaceuticals. The event takes place in May 2024 and highlights the institute's focus on integrating advanced technology and risk management strategies in oncology.
The Oncology Institute (NASDAQ: TOI) announced its Q1 2024 financial results, reporting a 24.2% increase in consolidated revenue to $95 million. Despite this, the gross profit decreased by 15.1% to $12 million, with net losses reducing to $19.9 million from the previous year's $30 million. The net loss per share improved to $(0.22) from $(0.33). Adjusted EBITDA was $(10.9) million, higher than the $(7.4) million from the prior year. The company ended Q1 with $66 million in cash and short-term investments. Operationally, TOI signed seven new capitation and value-based contracts across three states, integrated a capitated risk contract with a health plan in Florida, and expanded its MSO model in Florida. The firm also increased the number of scripts dispensed by 70% and hired seven new providers, bringing the total to 126 employed providers across 73 clinics. CEO Daniel Virnich highlighted the company's revenue growth and new partnerships as key milestones.
The Oncology Institute, Inc. (NASDAQ: TOI) disclosed that Dr. Daniel Virnich, TOI’s CEO, will join the 'Defining the Next Chapter in Value-Based Care' panel at the Leerink Healthcare Transformation Summit on May 16, 2024. TOI is a leading value-based oncology practice in the U.S.
FAQ
What is the current stock price of The Oncology Institute (TOIIW)?
